Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism

NCT02558270 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Metabolically Healthy Controls

Interventions

DRUG: Dapagliflozin
DRUG: Placebo

Sponsor

Medical University of Vienna